2019
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age
2015
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal Of Clinical Oncology 2015, 33: 4267-4276. PMID: 26598753, DOI: 10.1200/jco.2015.63.7801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsianBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantComorbidityDatabases, FactualFemaleHispanic or LatinoHumansInsurance CoverageInsurance, HealthMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsPathologic complete responseNational Cancer Data BaseNeoadjuvant chemotherapyBreast cancerEstrogen receptorWhite womenPositive tumorsAsian womenHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Timing of chemotherapyClinical T stageGrowth factor receptor 2Triple-negative tumorsPatient's zip codeHigh-grade tumorsRacial differencesZip codesFactor receptor 2Chemotherapy useComorbidity indexComplete responseT stageGrade tumors
2010
The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ
Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ. The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 130-133. PMID: 20956816, PMCID: PMC5161061, DOI: 10.1093/jncimonographs/lgq022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCombined Modality TherapyDisease ProgressionFemaleHumansIncidenceMastectomyMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrognosisRadiotherapy, AdjuvantRandomized Controlled Trials as TopicTamoxifenTreatment OutcomeConceptsBreast-conserving surgeryDuctal carcinomaInvasive carcinomaWhole breast radiation therapyImpact of surgeryTerms of recurrenceInvasive recurrenceRecurrent DCISDCIS recurrenceSystemic treatmentObservational studyRadiation therapyEquivalent outcomesCarcinomaMastectomyRecurrenceDCISSurgeryTamoxifenLower ratesOutcomesWomenLumpectomyPatientsMEDLINE